Trial Profile
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer; Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 17 May 2018 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
- 09 Oct 2017 Results from 5-year analysis (data cut off October 13, 2016 n=162) published in the Journal of Clinical Oncology.